A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer

NCT00046800 Phase 2 COMPLETED

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Details

Lead sponsor	Astellas Pharma Inc
Phase	Phase 2
Status	COMPLETED
Enrolment	80
Start date	2002-09
Completion	2003-03

Conditions

• Ovarian Neoplasms

Interventions

• OSI-211 (Liposomal Lurtotecan)

Countries

United States, United Kingdom